DoxyPEP is a morning-after pill to prevent sexually transmitted infections

Vox

Years after it was first proven to work, a new tool for preventing sexually transmitted infections is on the brink of entering mainstream medicine. That tool is doxyPEP, an antibiotic that works like a morning-after pill — but instead of preventing pregnancy within hours of unprotected sex, it prevents STIs like chlamydia and syphilis.

Dr. Connie Celum, professor of global health and of medicine at the UW, is referenced.

Widely available antibiotic helps prevent bacterial STIs in certain populations, UW clinical trial finds

The Seattle Times

New research has found an antibiotic that’s been around for decades could help prevent sexually transmitted bacterial diseases, according to a recent University of Washington clinical trial that proved so effective in certain populations it ended early.

Dr. Connie Celum, a UW professor of global health, medicine and epidemiology co-led the research.

Global Health Researchers Receive $122 Million to Study Monthly HIV Pill

Global health researchers at the University of Washington have received a $122 million grant from the Bill & Melinda Gates Foundation to test the effectiveness of the candidate drug islatravir, a once-a-month oral pill to prevent HIV.

The five-year grant will support the implementation of a Phase 3, randomized trial of islatravir, among women, in seven countries in sub-Saharan Africa. Islatravir is a nucleoside reverse transcriptase translocation inhibitor in development by Merck for the treatment and prevention of HIV-1 infection.

Point-of-Care HIV Viral Load Testing Combined with Task Shifting to Improve Treatment Outcomes (The Lancet - Includes Paul Drain, Ruanne Barnabas, and Connie Celum)

Point-of-care HIV viral load testing combined with task shifting can improve viral suppression and retention in care by up to 14% and enable rapid care decisions, suggest results of a clinical trial led by the University of Washington and the Centre for the AIDS Programme of Research in South Africa (CAPRISA).

Family Practice News: Oral HIV PrEP Also Protects Against Herpes

By Bruce Jancin

DURBAN, SOUTH AFRICA – Oral antiretroviral pre-exposure prophylaxis (PrEP) against HIV also reduces the risk of acquiring herpes simplex virus type 2, according to research presented at the 21st International AIDS Conference.

“Given the limited interventions for primary prevention of HSV-2, efficacy against HSV-2 provides additional benefit to oral PrEP,” observed Connie Celum, MD, professor of global health and medicine at the University of Washington, Seattle.

Fox News: Experimental Gel Partially Protects against Genital Herpes

By Rueters

An experimental vaginal gel containing a drug used to treat the AIDS virus could prevent half of cases of genital herpes, according to a study done in South Africa.

Among women who used tenofovir gel, the annual rate of infection with the genital herpes virus, known as herpes simplex virus type 2 or HSV-2, was 10.2 percent versus a rate of 21 percent for women who used a placebo gel.